{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:01:21Z","timestamp":1784224881729,"version":"3.55.0"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jbo.2025.100669","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T16:40:19Z","timestamp":1740760819000},"page":"100669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3408-0461","authenticated-orcid":false,"given":"M.","family":"Talarico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cattabriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Manzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Restuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Masci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Puppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Iezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Rizzello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pantani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-7305","authenticated-orcid":false,"given":"E.","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474086.2013.874943","article-title":"Management of bone disease in multiple myeloma","volume":"7","author":"Terpos","year":"2014","journal-title":"Expert Rev. Hematol."},{"issue":"5","key":"10.1016\/j.jbo.2025.100669_b0015","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jbo.2025.100669_b0020","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations","volume":"194","author":"Rosi\u00f1ol","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.jbo.2025.100669_b0025","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.jbo.2025.100669_b0030","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.jbo.2025.100669_b0035","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.jbo.2025.100669_b0040","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jbo.2025.100669_b0045","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group","volume":"7","author":"Hillengass","year":"2017","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.jbo.2025.100669_b0050","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.jbo.2025.100669_b0060","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM\/DFCI 2009 Trial","volume":"35","author":"Moreau","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.jbo.2025.100669_b0065","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jbo.2025.100669_b0070","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jbo.2025.100669_b0075","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","article-title":"Metabolic tumor volume assessed by 18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma","volume":"53","author":"Fonti","year":"2012","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.jbo.2025.100669_b0080","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1158\/1078-0432.CCR-16-0235","article-title":"Assessment of Total Lesion Glycolysis by 18F FDG PET\/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma","volume":"23","author":"McDonald","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.jbo.2025.100669_b0085","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1016\/j.ejrad.2012.06.028","article-title":"Contrast enhanced MRI and 18F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease","volume":"81","author":"Spinnato","year":"2012","journal-title":"Eur. J. Radiol."},{"issue":"9","key":"10.1016\/j.jbo.2025.100669_b0090","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0095","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.12346","article-title":"Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review","volume":"162","author":"Regelink","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.jbo.2025.100669_b0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2967\/jnumed.107.045641","article-title":"18F-FDG PET\/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma","volume":"49","author":"Fonti","year":"2008","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.jbo.2025.100669_b0105","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.jbo.2025.100669_b0110","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.jbo.2025.100669_b0115","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.jbo.2025.100669_b0120","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/bloodadvances.2022007052","article-title":"Utility of PET\/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma","volume":"6","author":"Charalampous","year":"2022","journal-title":"Blood Adv."},{"issue":"Supplement 1","key":"10.1016\/j.jbo.2025.100669_b0125","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2019-123143","article-title":"Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion","volume":"134","author":"Moreau","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jbo.2025.100669_b0130","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","article-title":"Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)","volume":"45","author":"Nanni","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.jbo.2025.100669_b0135","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.20.00386","article-title":"Standardization of 18F-FDG-PET\/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma","volume":"39","author":"Zamagni","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2025.100669_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102017","article-title":"Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial","volume":"60","author":"Zamagni","year":"2023","journal-title":"EClinicalMedicine."},{"issue":"11","key":"10.1016\/j.jbo.2025.100669_b0145","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3324\/haematol.2012.065359","article-title":"Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma","volume":"97","author":"Hillengass","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jbo.2025.100669_b0150","doi-asserted-by":"crossref","unstructured":"Hounsfield GN. Computed medical imaging. Nobel lecture, Decemberr 8, 1979. Journal of Computer Assisted Tomography. 1980, Vol. 4, 5, pp. 665-674.","DOI":"10.1097\/00004728-198010000-00017"},{"issue":"3","key":"10.1016\/j.jbo.2025.100669_b0155","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1148\/radiol.2015142631","article-title":"Dual- and Multi-Energy CT: Principles, Technical Approaches, and Clinical Applications","volume":"276","author":"McCollough","year":"2015","journal-title":"Radiology"},{"issue":"5 Suppl","key":"10.1016\/j.jbo.2025.100669_b0160","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.2214\/AJR.12.9116","article-title":"Dual-energy CT: general principles","volume":"1995","author":"Johnson","year":"2012","journal-title":"Am. J. Roentgenol."},{"issue":"7","key":"10.1016\/j.jbo.2025.100669_b0165","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/jimaging10070154","article-title":"What to Expect (and What Not) from Dual-Energy CT Imaging Now and in the Future?","volume":"10","author":"Garc\u00eda-Figueiras","year":"2024","journal-title":"Journal of Imaging."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/jcm13010264","article-title":"Imaging of Multiple Myeloma: Present and Future","volume":"13","author":"Rodr\u00edguez-Laval","year":"2024","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.jbo.2025.100669_b0175","doi-asserted-by":"crossref","first-page":"W324","DOI":"10.2214\/AJR.14.12613","article-title":"Dual-energy CT: virtual calcium subtraction for assessment of bone marrow involvement of the spine in multiple myeloma","volume":"204","author":"Thomas","year":"2015","journal-title":"Am. J. Roentgenol."},{"issue":"10","key":"10.1016\/j.jbo.2025.100669_b0180","doi-asserted-by":"crossref","first-page":"7664","DOI":"10.1007\/s00330-021-07821-0","article-title":"Quantitative and qualitative assessment of plasma cell dyscrasias in dual-layer spectral CT","volume":"31","author":"Brandelik","year":"2021","journal-title":"Eur. Radiol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0185","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1148\/radiol.2017170281","article-title":"Multiple Myeloma and Dual-Energy CT: Diagnostic Accuracy of Virtual Noncalcium Technique for Detection of Bone Marrow Infiltration of the Spine and Pelvis","volume":"286","author":"Kosmala","year":"2018","journal-title":"Radiology"},{"issue":"12","key":"10.1016\/j.jbo.2025.100669_b0190","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1007\/s00330-018-5537-5","article-title":"Dual-energy CT of the bone marrow in multiple myeloma: diagnostic accuracy for quantitative differentiation of infiltration patterns","volume":"28","author":"Kosmala","year":"2018","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.jbo.2025.100669_b0195","doi-asserted-by":"crossref","unstructured":"Brandelik SC, Skornitzke S, Mokry T et al. Quantitative and qualitative assessment of plasma cell dyscrasias in dual-layer spectral CT. European Radiology. 2021, Vol. 31, 10, pp. 7664-7673.","DOI":"10.1007\/s00330-021-07821-0"},{"issue":"2","key":"10.1016\/j.jbo.2025.100669_b0200","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.acra.2021.01.029","article-title":"Dual-Energy CT-Based Bone Marrow Imaging in Multiple Myeloma: Assessment of Focal Lesions in Relation to Disease Status and MRI Findings","volume":"29","author":"Werner","year":"2022","journal-title":"Acad. Radiol."},{"key":"10.1016\/j.jbo.2025.100669_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2020.109502","article-title":"Virtual calcium-suppression in dual energy computed tomography predicts metabolic activity of focal MM lesions as determined by fluorodeoxyglucose positron-emission-tomography","volume":"135","author":"Fervers","year":"2021","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.jbo.2025.100669_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.734819","article-title":"Radiotherapy Response Assessment of Multiple Myeloma: A Dual-Energy CT Approach With Virtual Non-Calcium Images","volume":"11","author":"Fervers","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbo.2025.100669_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2022.110223","article-title":"Correlation between whole skeleton dual energy CT calcium-subtracted attenuation and bone marrow infiltration in multiple myeloma","volume":"149","author":"Gu","year":"2022","journal-title":"Eur. J. Radiol."},{"issue":"4","key":"10.1016\/j.jbo.2025.100669_b0220","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s00330-020-07320-8","article-title":"Role of computed tomography texture analysis using dual-energy-based bone marrow imaging for multiple myeloma characterization: comparison with histology and established serologic parameters","volume":"31","author":"Reinert","year":"2021","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.jbo.2025.100669_b0225","first-page":"3","article-title":"Detecting bone marrow infiltration in nonosteolytic multiple myeloma through separation of hydroxyapatite via the two-material decomposition technique in spectral computed tomography","volume":"14","author":"Chen","year":"2024","journal-title":"Quant. Imaging Med. Surg."},{"key":"10.1016\/j.jbo.2025.100669_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2024.100636","article-title":"Diagnosis of newly developed multiple myeloma without bone disease detectable on conventional computed tomography (CT) scan by using dual-energy CT","volume":"48","author":"Jiang","year":"2024","journal-title":"Journal of Bone Oncology."},{"issue":"5","key":"10.1016\/j.jbo.2025.100669_b0235","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1159\/000531461","article-title":"Photon Counting Detector Computed Tomography: A New Frontier of Myeloma Bone Disease Evaluation","volume":"146","author":"Cook","year":"2023","journal-title":"Acta Haematol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0240","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1148\/radiol.220311","article-title":"Photon-counting Detector CT with Deep Learning Noise Reduction to Detect Multiple Myeloma","volume":"306","author":"Baffour","year":"2023","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.jbo.2025.100669_b0245","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00330-022-09225-0","article-title":"Myeloma bone disease imaging on a 1st-generation clinical photon-counting detector CT vs. 2nd-generation dual-source dual-energy CT","volume":"33","author":"Winkelmann","year":"2023","journal-title":"Eur. Radiol."},{"issue":"4","key":"10.1016\/j.jbo.2025.100669_b0250","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0255","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jbo.2025.100669_b0260","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.leukres.2013.06.002","article-title":"CXCR4 is a good survival prognostic indicator in multiple myeloma patients","volume":"37","author":"Bao","year":"2013","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.jbo.2025.100669_b0265","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15252\/emmm.201404698","article-title":"In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma","volume":"7","author":"Philipp-Abbrederis","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jbo.2025.100669_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100253","article-title":"The role of CXCR4 in multiple myeloma: Cells' journey from bone marrow to beyond","volume":"17","author":"Ullah","year":"2019","journal-title":"Journal of Bone Oncology."},{"key":"10.1016\/j.jbo.2025.100669_b0275","doi-asserted-by":"crossref","unstructured":"Lapa C, Schreder M, Schirbel A et al. [68Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values. Theranostics. 2017, Vol. 7, 1, pp. 205-212.","DOI":"10.7150\/thno.16576"},{"issue":"3","key":"10.1016\/j.jbo.2025.100669_b0280","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET\/CT","volume":"47","author":"Pan","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1136","key":"10.1016\/j.jbo.2025.100669_b0285","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20211272","article-title":"Imaging CXCR4 receptors expression for staging multiple myeloma by using 68Ga-Pentixafor PET\/CT: comparison with 18F-FDG PET\/CT","volume":"95","author":"Shekhawat","year":"2022","journal-title":"Br. J. Radiol."},{"issue":"10","key":"10.1016\/j.jbo.2025.100669_b0290","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s12149-021-01652-1","article-title":"Prognostic significance of 68Ga-Pentixafor PET\/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET\/CT and laboratory results","volume":"35","author":"Kuyumcu","year":"2021","journal-title":"Ann. Nucl. Med."},{"issue":"2","key":"10.1016\/j.jbo.2025.100669_b0295","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.jbo.2025.100669_b0300","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.7150\/thno.19050","article-title":"CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics."},{"issue":"10","key":"10.1016\/j.jbo.2025.100669_b0305","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2967\/jnumed.118.223420","article-title":"Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation","volume":"60","author":"Maurer","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jbo.2025.100669_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2021.796357","article-title":"Amino Acid and Proliferation PET\/CT for the Diagnosis of Multiple Myeloma","volume":"1","author":"Minamimoto","year":"2022","journal-title":"Front. Nucl. Med."},{"issue":"2","key":"10.1016\/j.jbo.2025.100669_b0315","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1148\/radiol.2422051980","volume":"242","author":"Dankerl","year":"2007","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.jbo.2025.100669_b0320","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00259-012-2333-3","article-title":"Clinical value of 11C-methionine PET\/CT in patients with plasma cell malignancy: comparison with 18F-FDG PET\/CT","volume":"40","author":"Nakamoto","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.jbo.2025.100669_b0325","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7150\/thno.13921","article-title":"11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement","volume":"6","author":"Lapa","year":"2016","journal-title":"Theranostics."},{"issue":"17","key":"10.1016\/j.jbo.2025.100669_b0330","doi-asserted-by":"crossref","first-page":"9895","DOI":"10.3390\/ijms23179895","article-title":"1C-Methionine PET\/CT in Assessment of Multiple Myeloma Patients: Comparison to 18F-FDG PET\/CT and Prognostic Value","volume":"23","author":"Morales-Lozano","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbo.2025.100669_b0335","first-page":"4","article-title":"Carbon-11-Labeled Methionine PET\/CT in Patients With FDG-Occult Multiple Myeloma: A Prospective Pilot Study","volume":"220","author":"Wang","year":"2022","journal-title":"Am. J. Roentgenol."},{"issue":"4","key":"10.1016\/j.jbo.2025.100669_b0340","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cpet.2024.06.001","article-title":"New PET Tracers for Symptomatic Myeloma","volume":"19","author":"Sagar","year":"2024","journal-title":"PET Clinics."},{"issue":"12","key":"10.1016\/j.jbo.2025.100669_b0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084840","article-title":"Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology","volume":"8","author":"L\u00fcckerath","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jbo.2025.100669_b0350","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s11307-022-01734-0","article-title":"Comparison of [18F]fluciclovine and [18F]FDG PET\/CT in Newly Diagnosed Multiple Myeloma Patients","volume":"24","author":"Stokke","year":"2022","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.jbo.2025.100669_b0355","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1477-7819-5-68","article-title":"11C-choline vs. 18F-FDG PET\/CT in assessing bone involvement in patients with multiple myeloma","volume":"5","author":"Nanni","year":"2007","journal-title":"World J. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.jbo.2025.100669_b0360","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/RLU.0000000000002638","article-title":"Comparison of 11C-Choline and 11C-Methionine PET\/CT in Multiple Myeloma","volume":"44","author":"Lapa","year":"2019","journal-title":"Clin. Nucl. Med."},{"issue":"11","key":"10.1016\/j.jbo.2025.100669_b0365","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00259-016-3392-7","article-title":"18F-fluorocholine versus 18F-fluorodeoxyglucose for PET\/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study","volume":"43","author":"Cassou-Mounat","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"10.1016\/j.jbo.2025.100669_b0370","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3390\/diagnostics13091570","article-title":"Multitracer PET\/CT with [18F]Fluorodeoxiglucose and [18F]Fluorocholine in the Initial Staging of Multiple Myeloma Patients Applying the IMPeTus Criteria: A Pilot Study","volume":"13","author":"Garrastachu Zumar\u00e1n","year":"2023","journal-title":"Diagnostics (basel)."},{"issue":"5","key":"10.1016\/j.jbo.2025.100669_b0375","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2967\/jnumed.113.131169","article-title":"11C-acetate PET\/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET\/CT","volume":"55","author":"Ho","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jbo.2025.100669_b0380","doi-asserted-by":"crossref","unstructured":"Lin C, Ho CL, Ng SH et al. (11)C-acetate as a new biomarker for PET\/CT in patients with multiple myeloma: initial staging and postinduction response assessment. European Journal of Nuclear Medicine and Molecular Imaging. 2014, Vol. 41, 1, pp. 41-49.","DOI":"10.1007\/s00259-013-2520-x"},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0385","doi-asserted-by":"crossref","first-page":"22188","DOI":"10.1038\/s41598-021-01740-2","article-title":"11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma","volume":"11","author":"Chen","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.jbo.2025.100669_b0390","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12149-014-0931-9","article-title":"Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET\/CT for the detection of active lesions of multiple myeloma","volume":"29","author":"Okasaki","year":"2015","journal-title":"Ann. Nucl. Med."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0395","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13550-018-0383-7","article-title":"Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET\/CT imaging","volume":"8","author":"Sachpekidis","year":"2018","journal-title":"EJNMMI Res."},{"issue":"8","key":"10.1016\/j.jbo.2025.100669_b0400","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1007\/s00259-023-06214-3","article-title":"Head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]FDG PET\/CT in multiple myeloma","volume":"50","author":"Souza","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jbo.2025.100669_b0405","unstructured":"EPS-205: Prospective Comparison of [18F]FDG and [68Ga]Ga-PSMA PET\/CT in Staging Multiple Myeloma. Di Franco M, Bezzi D, Talarico M et al. 2024. EANM."},{"issue":"4","key":"10.1016\/j.jbo.2025.100669_b0410","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/RLU.0000000000000629","article-title":"18F-FDG PET increases visibility of bone lesions in relapsed multiple myeloma: is this hypoxia-driven?","volume":"40","author":"De Waal","year":"2015","journal-title":"Clin. Nucl. Med."},{"issue":"7","key":"10.1016\/j.jbo.2025.100669_b0415","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00259-014-2721-y","article-title":"PET\/CT studies of multiple myeloma using (18)\u2009F-FDG and (18)\u2009F-NaF: comparison of distribution patterns and tracers' pharmacokinetics","volume":"41","author":"Sachpekidis","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.jbo.2025.100669_b0420","first-page":"148","article-title":"Treatment response evaluation with 18F-FDG PET\/CT and 18F-NaF PET\/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation","volume":"7","author":"Sachpekidis","year":"2017","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"10.1016\/j.jbo.2025.100669_b0425","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00277-015-2410-3","article-title":"Is there any complimentary role of F-18 NaF PET\/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET\/CT and F-18 FDG NaF PET\/CT","volume":"94","author":"Ak","year":"2015","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0430","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/tomography8010024","article-title":"Comparison of [68Ga]-FAPI PET\/CT and [18F]-FDG PET\/CT in Multiple Myeloma: Clinical Experience","volume":"8","author":"Elboga","year":"2022","journal-title":"Tomography."},{"issue":"3","key":"10.1016\/j.jbo.2025.100669_b0435","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1148\/radiol.2020192621","article-title":"CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging","volume":"295","author":"Ulaner","year":"2020","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.jbo.2025.100669_b0440","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","article-title":"Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0445","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/jmri.20349","article-title":"Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers","volume":"22","author":"Nos\u00e0s-Garcia","year":"2005","journal-title":"J. Magn. Reson. Imaging"},{"issue":"4","key":"10.1016\/j.jbo.2025.100669_b0450","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s13244-016-0492-7","article-title":"MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings","volume":"7","author":"Dutoit","year":"2016","journal-title":"Insights Imaging."},{"issue":"1088","key":"10.1016\/j.jbo.2025.100669_b0455","article-title":"Functional and molecular MRI of the bone marrow in multiple myeloma","volume":"91","author":"Koutoulidis","year":"2018","journal-title":"Br. J. Radiol."},{"issue":"9","key":"10.1016\/j.jbo.2025.100669_b0460","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ejrad.2013.04.012","article-title":"Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma","volume":"82","author":"Dutoit","year":"2013","journal-title":"Eur. J. Radiol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0465","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40644-024-00740-5","article-title":"DCE-MRI to distinguish all monoclonal plasma cell disease stages and correlation with diffusion-weighted MRI\/PET-based biomarkers in a hybrid simultaneous whole body-2-[18F]FDG-PET\/MRI imaging approach","volume":"24","author":"Jamet","year":"2024","journal-title":"Cancer Imaging"},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0470","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/bjh.14038","article-title":"Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma","volume":"174","author":"Hillengass","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0475","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-14-1029","article-title":"Dynamic contrast-enhanced magnetic resonance imaging for assessment of antiangiogenic treatment effects in multiple myeloma","volume":"21","author":"Merz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2025.100669_b0480","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1158\/1078-0432.CCR-06-0061","article-title":"Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma","volume":"13","author":"Hillengass","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.jbo.2025.100669_b0485","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1007\/s00330-015-3928-4","article-title":"Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study","volume":"16","author":"Merz","year":"2016","journal-title":"Eur. Radiol."},{"issue":"2","key":"10.1016\/j.jbo.2025.100669_b0490","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejrad.2015.11.040","article-title":"Combined evaluation of conventional MRI, dynamic contrast-enhanced MRI and diffusion weighted imaging for response evaluation of patients with multiple myeloma","volume":"85","author":"Dutoit","year":"2016","journal-title":"Eur. J. Radiol."},{"issue":"2","key":"10.1016\/j.jbo.2025.100669_b0495","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1148\/radiol.09090629","article-title":"Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging","volume":"254","author":"Lin","year":"2010","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0500","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00256-021-03903-8","article-title":"Review of diffusion-weighted imaging and dynamic contrast-enhanced MRI for multiple myeloma and its precursors (monoclonal gammopathy of undetermined significance and smouldering myeloma)","volume":"51","author":"Van Den Berghe","year":"2022","journal-title":"Skeletal Radiol."},{"issue":"4","key":"10.1016\/j.jbo.2025.100669_b0505","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.berh.2012.07.008","article-title":"Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure","volume":"26","author":"Bernstein","year":"2012","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0510","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1148\/radiol.2019181949","article-title":"Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS)","volume":"291","author":"Messiou","year":"2019","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.jbo.2025.100669_b0515","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2141.2011.08658.x","article-title":"Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology","volume":"153","author":"Hillengass","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0520","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40644-020-0286-5","article-title":"Quantification of tumor burden in multiple myeloma by atlas-based semi-automatic segmentation of WB-DWI","volume":"20","author":"Almeida","year":"2020","journal-title":"Cancer Imaging"},{"issue":"3","key":"10.1016\/j.jbo.2025.100669_b0525","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00256-022-04119-0","article-title":"Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis","volume":"52","author":"Torkian","year":"2023","journal-title":"Skeletal Radiol."},{"key":"10.1016\/j.jbo.2025.100669_b0530","doi-asserted-by":"crossref","unstructured":"Rasche L, Angtuaco E, McDonald JE et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017, Vol. 130, 1, pp. 30-34.","DOI":"10.1182\/blood-2017-03-774422"},{"issue":"12","key":"10.1016\/j.jbo.2025.100669_b0535","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s00277-020-04265-2","article-title":"Prospective comparison of 18-FDG PET\/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma","volume":"99","author":"Mesguich","year":"2020","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.jbo.2025.100669_b0540","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2214\/AJR.18.20989","article-title":"Comparison of Whole-Body DWI and 18F-FDG PET\/CT for Detecting Intramedullary and Extramedullary Lesions in Multiple Myeloma","volume":"213","author":"Chen","year":"2019","journal-title":"Am. J. Roentgenol."},{"issue":"5","key":"10.1016\/j.jbo.2025.100669_b0545","first-page":"479","article-title":"Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities","volume":"5","author":"Sachpekidis","year":"2015","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"8","key":"10.1016\/j.jbo.2025.100669_b0550","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1007\/s00259-020-05182-2","article-title":"Comparison of the diagnostic performance and impact on management of 18F-FDG PET\/CT and whole-body MRI in multiple myeloma","volume":"48","author":"Westerland","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"10.1016\/j.jbo.2025.100669_b0555","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.2021210048","article-title":"Prospective Evaluation of Whole-Body MRI versus FDG PET\/CT for Lesion Detection in Participants with Myeloma","volume":"3","author":"Messiou","year":"2021","journal-title":"Radiol. Imaging Cancer"},{"issue":"Supplement 2","key":"10.1016\/j.jbo.2025.100669_b0560","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S2152-2650(24)01855-X","article-title":"Prospective Functional Bone Disease Evaluation of Newly Diagnosed Multiple Myeloma with Combined Use of (18)F-FDG-PET\/CT and Whole-Body Diffusion Weighted Magnetic Resonance","volume":"24","author":"Talarico","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0565","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jbo.2025.100669_b0570","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1007\/s00330-021-07687-2","article-title":"Total diffusion volume in MRI vs. total lesion glycolysis in PET\/CT for tumor volume evaluation of multiple myeloma","volume":"31","author":"Terao","year":"2021","journal-title":"Eur. Radiol."},{"issue":"8","key":"10.1016\/j.jbo.2025.100669_b0575","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.3390\/cancers13081938","article-title":"Comparison of 18-FDG PET\/CT and Whole-Body MRI with Diffusion-Weighted Imaging in the Evaluation of Treatment Response of Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant","volume":"13","author":"Mesguich","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.jbo.2025.100669_b0580","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3892\/etm.2021.10259","article-title":"Whole-body diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient values as prognostic factors in multiple myeloma","volume":"22","author":"Costachescu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.jbo.2025.100669_b0585","article-title":"The Apparent Diffusion Coefficient of Diffusion-Weighted Whole-Body Magnetic Resonance Imaging Affects the Survival of Multiple Myeloma Independently","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2025.100669_b0590","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.14401","article-title":"Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response","volume":"176","author":"Latifoltojar","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.jbo.2025.100669_b0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229607","article-title":"Assessment of early treatment response on MRI in multiple myeloma: Comparative study of whole-body diffusion-weighted and lumbar spinal MRI","volume":"15","author":"Takasu","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jbo.2025.100669_b0600","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1148\/radiol.13131529","article-title":"Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma","volume":"271","author":"Giles","year":"2014","journal-title":"Radiology"},{"issue":"1020","key":"10.1016\/j.jbo.2025.100669_b0605","doi-asserted-by":"crossref","first-page":"e1198","DOI":"10.1259\/bjr\/52759767","article-title":"Assessing response of myeloma bone disease with diffusion-weighted MRI","volume":"85","author":"Messiou","year":"2012","journal-title":"Br. J. Radiol."},{"issue":"7","key":"10.1016\/j.jbo.2025.100669_b0610","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.acra.2017.12.008","article-title":"Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient: Preliminary Results From a Single-center Study","volume":"25","author":"Wu","year":"2018","journal-title":"Acad. Radiol."},{"issue":"Supplement 1","key":"10.1016\/j.jbo.2025.100669_b0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-139164","article-title":"Total Diffusion Volume Estimated By Whole-Body Diffusion Magnetic Resonance Imaging for the Assessment of Tumor Burden in Multiple Myeloma","volume":"136","author":"Narita","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2025.100669_b0620","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-199873","article-title":"Total Diffusion Volume Evaluated By Whole-Body Diffusion Weighted Magnetic Resonance Image for the Assessment of Tumor Burden in Multiple Myeloma; Relations with Measurable Residual Disease Evaluated By Next-Generation Flow Cytometry and Bone Marrow CD138","author":"Narita","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbo.2025.100669_b0625","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1148\/radiol.211388","article-title":"Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma","volume":"304","author":"Koutoulidis","year":"2022","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.jbo.2025.100669_b0630","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.jbo.2025.100669_b0635","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1002\/cam4.4136","article-title":"Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry","volume":"10","author":"Belotti","year":"2021","journal-title":"Cancer Med."},{"issue":"9","key":"10.1016\/j.jbo.2025.100669_b0640","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1002\/ajh.26995","article-title":"Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma","volume":"98","author":"Belotti","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.jbo.2025.100669_b0645","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2214\/AJR.21.26381","article-title":"Comparative Performance of Whole-Body MRI and FDG PET\/CT in Evaluation of Multiple Myeloma Treatment Response: Systematic Review and Meta-Analysis","volume":"218","author":"Rama","year":"2022","journal-title":"Am. J. Roentgenol."},{"issue":"Supplement 1","key":"10.1016\/j.jbo.2025.100669_b0650","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/blood-2023-180896","article-title":"Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma","volume":"142","author":"Schinke","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2025.100669_b0655","unstructured":"National Institute for Health and Care Excellence. Myeloma: diagnosis and management. NICE guideline [NG35]. [Online] 2018. https:\/\/www.nice.org.uk\/guidance\/ng35\/chapter\/Recommendations#imaging-investigations."},{"issue":"3","key":"10.1016\/j.jbo.2025.100669_b0660","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bjh.14827","article-title":"Guidelines for the use of imaging in the management of patients with myeloma","volume":"178","author":"Chantry","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.jbo.2025.100669_b0665","first-page":"469","article-title":"Comparison of (18)F-FDG PET\/CT and PET\/MRI in patients with multiple myeloma","volume":"5","author":"Sachpekidis","year":"2015","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"10.1016\/j.jbo.2025.100669_b0670","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1007\/s00330-021-08388-6","article-title":"Optimization of whole-body 2-[18F]FDG-PET\/MRI imaging protocol for the initial staging of patients with myeloma","volume":"32","author":"Burns","year":"2022","journal-title":"Eur. Radiol."},{"issue":"9","key":"10.1016\/j.jbo.2025.100669_b0675","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1007\/s00330-023-09593-1","article-title":"Hybrid simultaneous whole-body 2-[18F]FDG-PET\/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results","volume":"33","author":"Jamet","year":"2023","journal-title":"Eur. Radiol."},{"issue":"2","key":"10.1016\/j.jbo.2025.100669_b0680","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/10428194.2022.2142053","article-title":"Imaging minimal residual disease evaluation in multiple myeloma using [18F]FDG PET\/MRI","volume":"64","author":"Baril\u00e0","year":"2023","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.jbo.2025.100669_b0685","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1148\/rg.2019180096","article-title":"Whole-Body Imaging of Multiple Myeloma: Diagnostic Criteria","volume":"39","author":"Ormond Filho","year":"2019","journal-title":"Radiographics"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137425000107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137425000107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T13:20:42Z","timestamp":1742390442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137425000107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":137,"alternative-id":["S2212137425000107"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2025.100669","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2025.100669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100669"}}